BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 11834402)

  • 1. Increase of bone alkaline phosphatase after androgen deprivation therapy in patients with prostate cancer.
    Morote J; M'Hammed YI; Martinez E; Esquena S; Lorente JA; Gelabert A
    Urology; 2002 Feb; 59(2):277-80. PubMed ID: 11834402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
    Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R
    J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes and Prognostic Factors in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Recurrence after Radical Prostatectomy.
    Ravi P; Karnes RJ; Rangel LJ; Pagliaro LC
    J Urol; 2018 Nov; 200(5):1075-1081. PubMed ID: 29709664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PSA levels and the rate of positive surgical margins in radical prostatectomy specimens preceded by androgen blockade in clinical B2 (T2bNxMo) prostate cancer. The Lupron Depot Neoadjuvant Study Group.
    McLeod DG; Johnson CF; Klein E; Peabody JO; Coffield S; Soloway M
    Urology; 1997 Mar; 49(3A Suppl):70-3. PubMed ID: 9123740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of bone alkaline phosphatase as a marker for the diagnosis of osteoporosis in men under androgen ablation.
    Morote J; Trilla E; Esquena S; Abascal JM; Segura RM; Catalan R; Encabo G; Reventós J
    Int J Biol Markers; 2003; 18(4):290-4. PubMed ID: 14756545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of combined transient androgen deprivation and irradiation following radical prostatectomy for prostatic cancer.
    Eulau SM; Tate DJ; Stamey TA; Bagshaw MA; Hancock SL
    Int J Radiat Oncol Biol Phys; 1998 Jul; 41(4):735-40. PubMed ID: 9652832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results.
    Homma Y; Akaza H; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y;
    Int J Urol; 2004 May; 11(5):295-303. PubMed ID: 15147545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone alkaline phosphatase and prostate-specific antigen in the monitoring of prostate cancer.
    Cooper EH; Whelan P; Purves D
    Prostate; 1994 Nov; 25(5):236-42. PubMed ID: 7526352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone alkaline phosphatase serum level predicts the response to antiandrogen withdrawal.
    Morote J; Bellmunt J
    Eur Urol; 2002 Mar; 41(3):257-61. PubMed ID: 12180225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate specific antigen doubling time after radical prostatectomy: effect of neoadjuvant androgen deprivation therapy.
    Rabbani F; Perrotti M; Bastar A; Fair WR
    J Urol; 1999 Mar; 161(3):847-52. PubMed ID: 10022699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study.
    Siddiqui SA; Boorjian SA; Inman B; Bagniewski S; Bergstralh EJ; Blute ML
    J Urol; 2008 May; 179(5):1830-7; discussion 1837. PubMed ID: 18353378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intermittent androgen deprivation for clinically localized prostate cancer: initial experience.
    Grossfeld GD; Small EJ; Carroll PR
    Urology; 1998 Jan; 51(1):137-44. PubMed ID: 9457309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Additive effect of zoledronic acid on serum prostate-specific antigen changes for hormone-sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade.
    Kamiya N; Suzuki H; Endo T; Takano M; Yano M; Naoi M; Nishimi D; Kawamura K; Imamoto T; Ichikawa T
    Int J Urol; 2012 Feb; 19(2):169-73. PubMed ID: 22126137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cessation of long-term adjuvant androgen deprivation therapy after radical prostatectomy: is it feasible?
    Taguchi S; Fukuhara H; Morikawa T; Matsumoto A; Miyazaki H; Nakagawa T; Fujimura T; Kume H; Igawa Y; Homma Y
    Jpn J Clin Oncol; 2016 Dec; 46(12):1143-1147. PubMed ID: 27620729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate carcinoma staging. Clinical utility of bone alkaline phosphatase in addition to prostate specific antigen.
    Morote J; Lorente JA; Encabo G
    Cancer; 1996 Dec; 78(11):2374-8. PubMed ID: 8941009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome predictors of radical prostatectomy followed by adjuvant androgen deprivation in patients with clinical high risk prostate cancer and pT3 surgical margin positive disease.
    Spahn M; Briganti A; Capitanio U; Kneitz B; Gontero P; Karnes JR; Schubert M; Montorsi F; Scholz CJ; Bader P; van Poppel H; Joniau S;
    J Urol; 2012 Jul; 188(1):84-90. PubMed ID: 22578727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above.
    Kupelian PA; Buchsbaum JC; Elshaikh M; Reddy CA; Zippe C; Klein EA
    Cancer; 2002 Dec; 95(11):2302-7. PubMed ID: 12436435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Study of sexual hormone changes in prostate cancer patients before and after androgen deprivation therapy].
    Ying J; Yao DH; Ren XM
    Zhonghua Nan Ke Xue; 2003 Jun; 9(3):191-2, 196. PubMed ID: 12861832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A simple prognostic model involving prostate-specific antigen, alkaline phosphatase and albumin for predicting the time required to progress to castration-resistant prostate cancer in patients who received androgen deprivation therapy.
    Lv W; Shang H; Pei X; Chen Y; Xie H; He D; Wang X; Li L
    Int Urol Nephrol; 2017 Jan; 49(1):61-67. PubMed ID: 27837416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Duration of androgen deprivation therapy and nadir of testosterone at 20 ng/dL predict testosterone recovery to supracastrate level in prostate cancer patients who received external beam radiotherapy.
    Takei A; Sakamoto S; Wakai K; Tamura T; Imamura Y; Xu M; Maimaiti M; Kawamura K; Imamoto T; Komiya A; Akakura K; Ichikawa T
    Int J Urol; 2018 Apr; 25(4):352-358. PubMed ID: 29323427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.